Vasopressin Analogue
Pregnancy: C
Terlipressin (Vascular)
Brand names: Glypressin, Variquel
Adult dose
Dose: 1–2 mg IV bolus every 4–6 hours (oesophageal varices); 0.8–1.3 mg/h continuous infusion
Route: slow IV injection or infusion
Frequency: every 4–6 hours or continuous
Max: 2 mg per bolus
Used for variceal haemorrhage and hepatorenal syndrome; continue for up to 5 days; reduces portal pressure via splanchnic vasoconstriction
Paediatric dose
Dose: 20 micrograms/kg
Route: IV
Frequency: every 4–6 hours
Max: 1 mg per dose
Concentration: 1 mg/5 mL reconstituted micrograms/ml
Limited paediatric data; specialist use only for variceal haemorrhage
Dose adjustments
Renal
Use with caution in severe renal impairment
Hepatic
Use with caution; main indication is hepatic pathology
Paediatric weight-based calculator
Limited paediatric data; specialist use only for variceal haemorrhage
Clinical pearls
- CONFIRM trial: terlipressin improves 90-day survival in hepatorenal syndrome type 1
- Splanchnic vasoconstriction reduces portal blood flow — effective bridging to endoscopy/TIPS
- Contraindicated in septic shock — may cause dangerous systemic hypertension and tissue ischaemia
Contraindications
- Ischaemic heart disease
- Hypertension
- Peripheral vascular disease
- Septic shock
- Asthma (bronchoconstriction)
Side effects
- Hypertension
- Pallor
- Abdominal cramps
- Diarrhoea
- Bradycardia
- Ischaemia (cardiac, digital, splanchnic)
- Hyponatraemia
Interactions
- Beta-blockers (bradycardia)
- Drugs prolonging QT
Monitoring
- Blood pressure
- ECG (ischaemia monitoring)
- Serum sodium
- Urine output (HRS)
Reference: BNFc; BNF 86; CONFIRM trial; BSG variceal haemorrhage guidelines. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- SMART Risk Score for Recurrent CVD · Cardiovascular Risk
- Hachinski Ischaemic Score · Dementia
- Gustilo-Anderson Classification · Open Fractures
- Mangled Extremity Severity Score (MESS) · Limb Trauma
- WIfI Classification for Chronic Limb-Threatening Ischaemia · Vascular
- Calcium-Phosphate Product · Electrolytes
Drugs